Published in Drug Week, November 27th, 2009
HiFi DNA Tech has appealed to the U.S. Court of Appeals for the Second Circuit in Manhattan, asking the court to reverse the FDA's refusal to down-classify a human papillomarvirus (HPV) DNA replication device from a class III cancer test category to a class II virology device category or, in the alternative, remand the case to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.